The clinical development of new mitotic inhibitors that stabilize the microtubule.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Anti-Cancer Drugs

• Publication date

  2004-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1097/01.CAD.0000131681.21637.B2PMID 15205596
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The biology and medicinal chemistry of epothilones.

  2012cited by this paper
• Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

  2004cited by this paper
• Formal synthesis of (+)-discodermolide.

  2003cited by this paper
• Total synthesis of the potent microtubule-stabilizing agent (+)-discodermolide.

  2003cited by this paper
• Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)-discodermolide.

  2003cited by this paper
• Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

  2003cited by this paper
• EPO906 (epothilone B): a promising novel microtubule stabilizer.

  2003cited by this paper
• Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.

  2003cited by this paper
• Generation of novel epothilone analogs with cytotoxic activity by biotransformation.

  2003cited by this paper
• Design, synthesis, and biological properties of highly potent epothilone B analogues.

  2003cited by this paper
• BMS-247550 Bristol-Myers Squibb/GBF.

  2003cited by this paper
• Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+)-discodermolide.

  2002cited by this paper
• Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells.

  2002cited by this paper
• Clinical trials referral resource. Flavopiridol.

  2002cited by this paper
• Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.

  2002cited by this paper
• Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues.

  2001cited by this paper
• Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts

  2001cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• Anticancer therapy with novel tubulin-interacting drugs.

  2001cited by this paper
• Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines.

  2001cited by this paper
• The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies.

  2001cited by this paper
• Novel molecules that interact with microtubules and have functional activity similar to Taxol.

  2001cited by this paper
• Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.

  2000cited by this paper
• Synthesis and biological evaluation of highly potent analogues of epothilones B and D.

  2000cited by this paper
• The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells—preliminary comparisons to paclitaxel

  1998cited by this paper
• Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*

  1997cited by this paper
• The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.

  1997cited by this paper
• Total Synthesis of (–)‐Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure–Activity Relationships of the Epothilones

  1997cited by this paper
• Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.

  1996cited by this paper
• Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

  1995cited by this paper
• Clinical trials referral resource.

  1992cited by this paper
• DISCODERMOLIDE—A NEW, MARINE‐DERIVED IMMUNOSUPPRESSIVE COMPOUND: I. IN VITRO STUDIES

  1991cited by this paper

• Synthesis and structure-activity relationship study of water-soluble carbazole sulfonamide derivatives as new anticancer agents.

  2020cites this paper
• An overview on the synthetic and medicinal perspectives of indenopyrazoles.

  2019cites this paper
• Synthesis of Combretastatin‐A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach: in vitro Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization

  2019cites this paper
• Design and Synthesis of Pyrimidine Based Heterocycles as Potential Anti-cancer Agents with Combination Chemotherapeutic Potential or Targeted One Carbon Metabolism Inhibition and Anti-opportunistic Agents

  2019cites this paper
• Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis.

  2018cites this paper
• QSAR Modeling of the Arylthioindole Class of Colchicine Polymerization Inhibitors as Anticancer Agents.

  2017cites this paper
• Investigation of N-Arylsulfonylimidazole as Novel Scaffold for Anticancer Agents

  2016cites this paper
• Using Cytochalasins to Improve Current Chemotherapeutic Approaches

  2015cites this paper
• New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer.

  2015cites this paper
• Chapter 9 – Anticancer Drugs Targeting Tubulin and Microtubules

  2015cites this paper
• Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin

  2014cites this paper
• Synthesis and structure-activity relationship of 4-azaheterocycle benzenesulfonamide derivatives as new microtubule-targeting agents.

  2014cites this paper
• Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach.

  2014cites this paper
• Virtual screening and discovery of novel aurora kinase inhibitors.

  2014cites this paper
• Targeting Microtubules by Natural Agents for Cancer Therapy

  2014cites this paper
• Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation

  2014cites this paper
• Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.

  2013cites this paper
• 3D-QSAR and docking studies of benzoyl urea derivatives as tubulin-binding agents for antiproliferative activity

  2013cites this paper
• Novel brominated quinoline and pyrimidoquinoline derivatives as potential cytotoxic agents with synergistic effects of γ-radiation

  2012cites this paper
• Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents.

  2012cites this paper
• Novel therapeutics for the management of castration‐resistant prostate cancer (CRPC)

  2012cites this paper
• A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton

  2012cites this paper
• Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.

  2011cites this paper
• Structure-activity relationship study of arylsulfonylimidazolidinones as anticancer agents.

  2011cites this paper
• Design, Synthesis, Biological Evaluation, and Structure–Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4

  2011cites this paper
• Enantioselective total synthesis of (-)-zampanolide, a potent microtubule-stabilizing agent.

  2011cites this paper
• Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

  2011cites this paper
• Importance of Imidazolidinone Motif in 4-Phenyl-N-arylsulfonylimidazolidinone for their Anticancer Activity

  2011cites this paper
• Effect of the isosteric replacement of the phenyl motif with furyl (or thienyl) of 4-phenyl-N-arylsulfonylimidazolones as broad and potent anticancer agents

  2011cites this paper
• Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents.

  2011cites this paper
• Taxus spp.: Botany, Horticulture, and Source of Anti‐Cancer Compounds

  2010cites this paper
• NRPS/PKS hybrid enzymes and their natural products

  2010cites this paper
• Iron Complexation to Oxygen Rich Marine Natural Products: A Computational Study

  2010cites this paper
• A Novel Synthetic Analog of 5, 8-Disubstituted Quinazolines Blocks Mitosis and Induces Apoptosis of Tumor Cells by Inhibiting Microtubule Polymerization

  2010cites this paper
• ASK1-P38 pathway is important for anoikis induced by microtubule-targeting aryl chloroethylureas.

  2010cites this paper
• Synthesis, in‐vitro Cytotoxicity, and a Preliminary Structure‐Activity Relationship Investigation of Pyrimido[4,5‐c]quinolin‐1(2H)‐ones

  2010cites this paper
• Drug Safety Evaluation

  2009cites this paper
• New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies.

  2009cites this paper
• DEVELOPMENT, CHARACTERIZATION AND IMAGING OF BONE METASTASIS MOUSE MODELS - THE EFFECT OF SAGOPILONE ON TUMOR GROWTH AND BONE RESORPTION -

  2009cites this paper
• Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

  2009cites this paper
• The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

  2008cites this paper
• Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors

  2008cites this paper
• Epothilones in breast cancer: current status and future directions

  2008cites this paper
• Structural studies of taxol analogues for drug discovery

  2008cites this paper
• Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.

  2008cites this paper
• Design, synthesis and biological evaluation of bridged epothilone D analogues.

  2008cites this paper
• Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains.

  2008cites this paper
• Ixabepilone for the treatment of solid tumors: a review of clinical data.

  2008cites this paper
• LINKING INSIGHTS FROM ECOLOGICAL RESEARCH WITH BIOPROSPECTING TO PROMOTE CONSERVATION , ENHANCE RESEARCH CAPACITY , AND PROVIDE ECONOMIC USES OF BIODIVERSITY

  2008cites this paper
• Ixabepilone for the treatment of solid tumors: a review of clinical data

  2008cites this paper
• Challenging patient populations in breast cancer: Taxane resistance and triple‐negative receptor subtype

  2008cites this paper
• Anticancer Drugs Targeting Tubulin and Microtubules

  2008cites this paper
• Linking bioprospecting with sustainable development and conservation: the Panama case

  2007cites this paper
• Microtubule-stabilizing natural products as promising cancer therapeutics.

  2007cites this paper
• The Chemistry and Biology of Epothilones—The Wheel Keeps Turning

  2007cites this paper
• Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

  2007cites this paper
• Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.

  2007cites this paper
• Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.

  2007cites this paper
• Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies.

  2007cites this paper
• Taxane refractory prostate cancer.

  2007cites this paper
• A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors

  2007cites this paper
• THE IN VITRO METABOLISM OF THREE ANTICANCER DRUGS

  2007cites this paper
• Enhanced microtubule binding and tubulin assembly properties of conformationally constrained paclitaxel derivatives.

  2007cites this paper
• Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.

  2007cites this paper
• Advances in mitotic inhibitors for cancer treatment.

  2006cites this paper
• 4'-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3',4',5'-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents.

  2006cites this paper
• Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

  2006cites this paper
• Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors

  2006cites this paper
• Resistance To Taxanes

  2006cites this paper
• Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

  2006cites this paper
• Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

  2005cites this paper
• Interacciones de los microtúbulos con ligandos activadores de tubulina

  2005cites this paper
• Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel.

  2005cites this paper
• The epothilone dilemma.

  2005cites this paper
• PHARMACOLOGICAL AND STRUCTURE-ACTIVITY RELATIONSHIP EVALUATION OF MICROTUBULE-STABILIZING AGENTS

  2005cites this paper
• Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments

  2005cites this paper
• Microtubule-interfering activity of parthenolide.

  2004cites this paper
• Targeting Microtubules by Natural Agents for Cancer Therapy Microtubules: Important Target for Cancer Therapy Molecular Cancer Therapeutics

  year unknowncites this paper
• Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Update on Options for Treatment of Metastatic Castration-resistant Prostate Cancer

  year unknowncites this paper